Crestor Helps Shelter AstraZeneca From Economic Storm
This article was originally published in The Pink Sheet Daily
Executive Summary
Unlike other Big Pharmas, firm also gets a temporary reprieve from generic erosion of two brands.
You may also be interested in...
AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix
AstraZeneca and Abbott announce co-promotion agreement for TriLipix ahead of an FDA decision on a jointly-developed investigational Crestor/TriLipix compound.
ASCO Abstracts Hold Some Surprises Including Data On AZ’s Vandetanib, Bristol’s Ipilimumab
Despite the lack of innovative drugs highlighted in ASCO's media briefing on its upcoming annual meeting, there is a range of oncology development updates that will be presented - including some surprises
Bristol/AZ Saxagliptin Review Deadline Pushed Back; Tea Leaves Still Look Good For Approval
Bristol and FDA are working on cardiovascular outcomes study proposal. New deadline is July 30.